Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Retained Earnings: 2021-2024

Historic Retained Earnings for Krystal Biotech (KRYS) over the last 4 years, with Dec 2024 value amounting to -$180.7 million.

  • Krystal Biotech's Retained Earnings rose 87.96% to -$27.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$27.2 million, marking a year-over-year increase of 87.96%. This contributed to the annual value of -$180.7 million for FY2024, which is 33.04% up from last year.
  • As of FY2024, Krystal Biotech's Retained Earnings stood at -$180.7 million, which was up 33.04% from -$269.8 million recorded in FY2023.
  • Krystal Biotech's 5-year Retained Earnings high stood at -$140.8 million for FY2021, and its period low was -$280.8 million during FY2022.
  • Over the past 3 years, Krystal Biotech's median Retained Earnings value was -$269.8 million (recorded in 2023), while the average stood at -$243.8 million.
  • Its Retained Earnings has fluctuated over the past 5 years, first plummeted by 99.43% in 2022, then surged by 33.04% in 2024.
  • Over the past 4 years, Krystal Biotech's Retained Earnings (Yearly) stood at -$140.8 million in 2021, then tumbled by 99.43% to -$280.8 million in 2022, then rose by 3.89% to -$269.8 million in 2023, then soared by 33.04% to -$180.7 million in 2024.